نتائج البحث - Shubham Pant

تنقيح النتائج
  1. 1
    Treatment of Breast Cancer With Trastuzumab During Pregnancy

    Treatment of Breast Cancer With Trastuzumab During Pregnancy حسب Shubham Pant, Mark B. Landon, Michael L. Blumenfeld, William Farrar, Charles L. Shapiro

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Pancreas Cancer-Associated Pain Management

    Pancreas Cancer-Associated Pain Management حسب Andrew L. Coveler, Jonathan D. Mizrahi, Bory Eastman, Smith Apisarnthanarax, Shalini Dalal, Terry A. McNearney, Shubham Pant

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Adagrasib in Advanced Solid Tumors Harboring a <i>KRAS</i><sup><i>G12C</i></sup> Mutation

    Adagrasib in Advanced Solid Tumors Harboring a <i>KRAS</i><sup><i>G12C</i></sup> Mutation حسب Tanios Bekaii‐Saab, Rona Yaeger, Alexander I. Spira, Meredith Pelster, Joshua K. Sabari, Navid Hafez, Minal Barve, Karen Velastegui, Xiaohong Yan, Aditya Shetty, Hirak Der‐Torossian, Shubham Pant

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

    A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer حسب Johanna C. Bendell, Anna M. Varghese, David M. Hyman, Todd M. Bauer, Shubham Pant, Sophie Callies, Ji Lin, Ricardo Martínez, Enaksha Wickremsinhe, Aaron Alan Fink, Volker Wacheck, Kathleen N. Moore

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older

    Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older حسب Jonathan D. Mizrahi, Jane E. Rogers, Kenneth R. Hess, Robert A. Wolff, Gauri R. Varadhachary, Milind Javle, Rachna T. Shroff, Linus Ho, David R. Fogelman, Kanwal Raghav, Michael J. Overman, Shubham Pant

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors

    A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors حسب Shubham Pant, Mansoor N. Saleh, Johanna C. Bendell, Jeffrey R. Infante, Suzanne F. Jones, Carla Kurkjian, Kathleen N. Moore, Julia Kazakin, Giovanni Abbadessa, Y. Wang, Y. Chen, Brian Schwartz, Luis H. Camacho

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers

    Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers حسب Mohamed A. Gouda, Helen J. Huang, Sarina A. Piha‐Paul, S. Greg Call, Daniel D. Karp, Siqing Fu, Aung Naing, Vivek Subbiah, Shubham Pant, Derek Dustin, Apostolia M. Tsimberidou, David S. Hong, Jordi Rodón, Funda Meric‐Bernstam, Filip Janků

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer

    Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer حسب Benny Johnson, Jonathan M. Loree, Alexandre A. Jácome, Shehara Mendis, Muddassir Syed, Van K. Morris, Christine M. Parseghian, Arvind Dasari, Shubham Pant, Victoria M. Raymond, Eduardo Vilar, Michael J. Overman, Bryan K. Kee, Cathy Eng, Kanwal Raghav, Scott Kopetz

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    PD-023 Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

    PD-023 Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) prev... حسب L.-T. Chen, Jens T. Siveke, Andrea Wang‐Gillam, Richard Hubner, Shubham Pant, Tomislav Dragovich, Vincent Chung, David Chang, Paul J. Ross, Prasad Cooray, Niall C. Tebbutt, F. Franke, Bruce Belanger, Navreet Dhindsa, F. de Jong, Khalid Mamlouk, Daniel D. Von Hoff

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors

    A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid t... حسب Carol Aghajanian, Katherine M. Bell‐McGuinn, Howard A. Burris, Lillian L. Siu, Lee-Ann Stayner, Jennifer J. Wheler, David S. Hong, Carla Kurkjian, Shubham Pant, Ademi Santiago-Walker, Jennifer Gauvin, Joyce Antal, Joanna Opalinska, Shannon R. Morris, Jeffrey R. Infante

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mTOR/AKT/PI3K</i> Pathway Alterations and Advanced Solid Malignancies

    Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mTOR/AKT/PI3K</i> Pathway Alterations and Advanced Solid Maligna... حسب Vivek Subbiah, Niamh Coleman, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Filip Janků, Jordi Rodón, Shubham Pant, Ecaterina E. Dumbrava, Siqing Fu, David S. Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric‐Bernstam, Aung Naing

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors

    First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors حسب Todd M. Bauer, Byoung Chul Cho, Rebecca S. Heist, Lyudmila Bazhenova, Theresa L. Werner, Sanjay Goel, Dong‐Wan Kim, Douglas Adkins, Richard D. Carvajal, Ajjai Alva, Keith D. Eaton, Judy Wang, Yong Liu, Xiaohong Yan, Jamie Christensen, Saskia Neuteboom, Richard C. Chao, Shubham Pant

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers

    Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers حسب Natalie Ngoi, Tin‐Yun Tang, Catia Fava Gaspar, Dean C. Pavlick, Gregory M. Buchold, Emma L. Scholefield, Vamsi Parimi, Richard S.P. Huang, Tyler Janovitz, Natalie Danziger, Mia Levy, Shubham Pant, Anaemy Danner De Armas, David Kumpula, Jeffrey S. Ross, Milind Javle, Jordi Rodón

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer

    A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer حسب Shubham Pant, Suzanne F. Jones, Carla Kurkjian, Jeffrey R. Infante, Kathleen N. Moore, Howard A. Burris, D. Scott McMeekin, Karim A. Benhadji, Bharvin K.R. Patel, Martin Frenzel, Jonathan D. Kursar, Maciej J. Zamek‐Gliszczynski, Eunice Yuen, Edward M. Chan, Johanna C. Bendell

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

    Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma حسب Mouhammed Amir Habra, Bettzy Stephen, Matthew T. Campbell, Kenneth R. Hess, Coya Tapia, Mingxuan Xu, Jordi Rodón, Camilo Jiménez, Jeffrey E. Lee, Nancy D. Perrier, Russell R. Boraddus, Shubham Pant, Vivek Subbiah, David S. Hong, Abdulrazzak Zarifa, Siqing Fu, Daniel D. Karp, Funda Meric‐Bernstam, Aung Naing

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma

    Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma حسب Giampaolo Perri, Laura Prakash, Wei Qiao, Gauri R. Varadhachary, Robert A. Wolff, David R. Fogelman, Michael J. Overman, Shubham Pant, Milind Javle, Eugene J. Koay, Joseph M. Herman, Michael P. Kim, Naruhiko Ikoma, Ching‐Wei D. Tzeng, Jeffrey E. Lee, Matthew H. G. Katz

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

    First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors حسب Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham Pant, Arthur E. Frankel, Peter Schmid, Kathleen N. Moore, William McCulloch, Katharine Grimmer, Marie O’Farrell, George Kemble, Howard A. Burris

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer

    Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer حسب Giampaolo Perri, Laura Prakash, Huamin Wang, Priya Bhosale, Gauri R. Varadhachary, Robert A. Wolff, David R. Fogelman, Michael J. Overman, Shubham Pant, Milind Javle, Eugene J. Koay, Joseph M. Herman, Michael P. Kim, Naruhiko Ikoma, Ching‐Wei D. Tzeng, Jeffrey E. Lee, Matthew H. G. Katz

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

    Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer حسب Martin H. Voss, Michael S. Gordon, Monica Mita, Brian I. Rini, Vicky Makker, Teresa Macarulla, David C. Smith, Andrés Cervantes, Igor Puzanov, Роберто Пили, Ding Wang, Shadia I. Jalal, Shubham Pant, Manish R. Patel, Rachel Neuwirth, Aaron Enke, Yaping Shou, Farhad Sedarati, Douglas V. Faller, Howard A. Burris

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Doublecortin-Like Kinase 1 Is Elevated Serologically in Pancreatic Ductal Adenocarcinoma and Widely Expressed on Circulating Tumor Cells

    Doublecortin-Like Kinase 1 Is Elevated Serologically in Pancreatic Ductal Adenocarcinoma and Widely Expressed on Circulating Tumor Cells حسب Dongfeng Qu, Jeremy Johnson, Parthasarathy Chandrakesan, Nathaniel Weygant, Randal May, Nicole M. Aiello, Andrew D. Rhim, Lichao Zhao, Wei Zheng, Stanley Lightfoot, Shubham Pant, Jeremy Irvan, Russell G. Postier, James R. Hocker, Jay S. Hanas, Naushad Ali, Sripathi M. Sureban, Guangyu An, Michael Schlosser, Ben Z. Stanger, Courtney W. Houchen

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: